A	B	C
1	Main
2		Brand Name	PRO70769, rHUmab 2H7
3		Generic Name	ocrelizumab
4		Indication	Rheumatoid Arthritis
5		Mechanism	Humanized Anti-CD20
6		Economics	BIIB, Roche. BIIB receives 30% of the first $50m operating profit of Rituxan and 40% of profits thereafter.
7			For ocrelizumab, BIIB will receive 38% of operating profit, followed by 35% followed by 30% (at $150m and $350m).
8			The new economics will also apply to Rituxan.
9			The decision-making process is being disputed by the partners and will be decided by an arbitrator.
10		Clinical Studies
11			Phase III Rheumatoid Arthritis - n=1000 STAGE - MTX-refractory - Initiated Q4 2006
12
13			Phase III Rheumatoid Arthritis - SCRIPT - TNF-refractory - Initiated Q2 2007 - Results in 2009
14
15			Phase III Rheumatoid Arthritis - FILM - MTX-naïve - Initiated Q2 2007
16
17			Phase III LN - Initiate YE07
18			Study shut down?
19
20			Phase III SLE - Initiate in 2008
21			Study shut down?
22
23			Phase II UC - Initiate YE07
24
25			Phase III RRMS - Initiate 2008 - Results Late 2009?